Novavax (NVAX) Research & Development (2010 - 2026)

Novavax's Research & Development history runs 17 years deep, the most recent figure standing at $95.5 million for Q1 2026.

• On a quarterly basis, Research & Development rose 7.35% year-over-year to $95.5 million in Q1 2026; TTM through Mar 2026 was $348.9 million, a 9.96% decrease from a year earlier, with the FY2025 full-year figure at $342.3 million, down 12.49% from the prior year.
• Research & Development grew to $95.5 million in Q1 2026 per NVAX's latest filing, from $75.9 million in the prior quarter.
• Across five years, Research & Development topped out at $383.5 million in Q1 2022 and bottomed at $75.9 million in Q4 2025.
• The 5-year median for Research & Development is $106.2 million (2023), against an average of $164.8 million.
• Across the five-year window, Research & Development tumbled 73.22% in 2022 and advanced 12.75% in 2025, its largest moves.
• Year by year, Research & Development stood at $257.8 million in 2022, then sank by 36.13% to $164.7 million in 2023, then sank by 36.62% to $104.4 million in 2024, then decreased by 27.31% to $75.9 million in 2025, then climbed by 25.83% to $95.5 million in 2026.
• Per Business Quant, the three latest NVAX Research & Development figures stand at $95.5 million (Q1 2026), $75.9 million (Q4 2025), and $98.3 million (Q3 2025).